24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
CytoReason
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:56
Mobileye first quarter revenue falls by almost 50% as clients cut back on spending to clear excess stock
14:00
Melio names Boaz BenDavid as its first Chief Financial Officer
13:28
Check Point registers higher than expected Q1 profit helped by growth of AI-powered security platform
09:26
Microsoft explains how Generative AI impacts IP law and compliance
More stories
Buzz
Most popular
Daily
Weekly
1
Nvidia announces $700 million acquisition of Run:ai
2
Nvidia on verge of completing $700 million acquisition of Run:ai
3
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
4
Nvidia continues Israel shopping spree with acquisition of Deci
5
Nagomi Security raises $23 million Series A for proactive defense platform
More news
CytoReason
3 stories about CytoReason
CytoReason raises $20 million from Pfizer for AI drug discovery and development platform
20.09.22
|
Meir Orbach
Pfizer will also have options to license the Israeli startup’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110 million over the next five years
CytoReason enters Japanese market with SPI partnership
30.09.21
|
James Spiro
This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development
Pfizer Taps Israeli Machine Learning Drug Discovery Company CytoReason
10.01.19
|
Lilach Baumer
Under the agreement, CytoReason will receive payments "potentially equaling up to low double digit millions" of dollars
Please ensure Javascript is enabled for purposes of
website accessibility